1550-P: Changes in Beta-Cell Function during Dapagliflozin Therapy in Combination with Exenatide in Type 2 Diabetes Patients (T2D)

Introduction dapagliflozin DAPA, n=25; exenatide EXE, n=25; or both DAPA/EXE, n=25, and (ii) after 1 and 4 months of therapy (CHRONIC study) with PCB, DAPA, EXE or DAPA/EXE. Matsuda Index MI, Insulin Secretion ΔI/ΔG)0-3h) and Disposition Index [DI=IS x MI were calculated using standard formulae. MI was corrected for urinary glucose excretion. Conclusion: Dapagliflozin and exenatide as monotherapy improve beta cell function (DI) acutely and chronically (4 months). Combination therapy with dapagliflozin plus exenatide leads to superior and sustained improvement in beta cell function (DI) compared to either drug alone. These data suggest that combination therapy with GLP-1 RA plus SGLT2i may enhance long-term preservation of beta-cell function in T2D patients. Disclosure R.A. DeFronzo: Advisory Panel; AstraZeneca, Novo Nordisk, Boehringer-Ingelheim, Intarcia Therapeutics, Inc., Aardvark, Renalytix, Corcept Therapeutics, Alnylam Pharmaceuticals, Inc. Research Support; Boehringer-Ingelheim, AstraZeneca, 89bio, Inc., Amgen Inc., Medality, Corcept Therapeutics. Speaker's Bureau; AstraZeneca, Corcept Therapeutics, Renalytix. G. Baskoy: None. C.L. Triplitt: Speaker's Bureau; Novo Nordisk. Consultant; Eli Lilly and Company. Other Relationship; American Diabetes Association. E. Cersosimo: None. C. Solis-Herrera: Advisory Panel; Novo Nordisk, Bayer Inc. J.M. Adams: None. A.A. Hansis-Diarte: None. A. Gastaldelli: Consultant; Boehringer-Ingelheim. Other Relationship; Pfizer Inc., Eli Lilly and Company. Consultant; Merck Sharp Novo Nordisk. Speaker's Bureau; Merck Sharp Pfizer Inc. Speaker's Bureau; Novo Nordisk. A. Chavez: None.